Preliminary report on tumor stem cell/B cell hybridoma vaccine for recurrent glioblastoma multiforme
BACKGROUND: Glioblastoma multiforme (GBM), the most aggressive glioma, presents with a rapid evolution and relapse within the first year, which is attributed to the persistence of tumor stem cells (TSC) and the escape of immune surveillance. Mixed leukocyte culture (MLC) cytoimplant has been shown t...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2008-01-01
|
Series: | Hematology/Oncology and Stem Cell Therapy |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1658387608500549 |
id |
doaj-f89733f5bf1548a695abea82e4264011 |
---|---|
record_format |
Article |
spelling |
doaj-f89733f5bf1548a695abea82e42640112020-11-25T00:59:52ZengElsevierHematology/Oncology and Stem Cell Therapy1658-38762008-01-0111313Preliminary report on tumor stem cell/B cell hybridoma vaccine for recurrent glioblastoma multiformeGustavo A. Moviglia0Antonio G. Carrizo1Gabriela Varela2Carlos A. Gaeta3Andrea Paes de Lima4Pablo Farina5Hugo Molina6Fundación Regina Mater, Buenos Aires, Argentina; CIITT from Universidad Maimónides, Buenos Aires, Argentina; Gustavo Antonio Moviglia, MD·Instituto Regina Mater·Paraguay 2452, Buenos Aires, 1121 ABL Argentina·T: +541149626800 ext 221·F: +54114962 6800 ext 248Fundación Regina Mater, Buenos Aires, ArgentinaFundación Regina Mater, Buenos Aires, ArgentinaFundación Regina Mater, Buenos Aires, Argentina; CIITT from Universidad Maimónides, Buenos Aires, ArgentinaFundación Regina Mater, Buenos Aires, ArgentinaFundación Regina Mater, Buenos Aires, ArgentinaCIITT from Universidad Maimónides, Buenos Aires, ArgentinaBACKGROUND: Glioblastoma multiforme (GBM), the most aggressive glioma, presents with a rapid evolution and relapse within the first year, which is attributed to the persistence of tumor stem cells (TSC) and the escape of immune surveillance. Mixed leukocyte culture (MLC) cytoimplant has been shown to function as a powerful intratumor pro-inflammatory cytokine pump. Tumor B-cell hybridoma (TBH) vaccines have been shown to function as antigen-presenting cells. We evaluated the toxicity and efficiency of each treatment alone and in combination. PATIENTS AND METHODS: In an open study, 12 consecutive patients were evenly divided into 3 groups, each group receiving 3 different treatments. Patients in Group 1 were treated, after diagnosis, with debulking surgery (DS)+radiotherapy (Rx), and after the first relapse underwent DS+MLC treatment. Patients in Group 2 were similarly treated but after the first relapse underwent DS+MLC+TBH. Finally, patients in Group 3 were similarly treated but after the first relapse underwent DS+TBH. Nestin PAP stain assessed TSC participation in TBH. RESULTS: Treatment with MLC had strong and rapid therapeutic effects, but was limited in duration and induced various degrees of brain inflammation. Treatment with MLC+TBH acted synergistically, provoking a rapid, strong and lasting therapeutic response but also generating different degrees of brain inflammation. A lasting therapeutic effect without generating high degrees of brain inflammation occurred in patients treated with TBH vaccine alone. CONCLUSION: TSC vaccine consisting of TBH alone seems to have potent adjuvant reactions overcoming both persistence of tumor stem cells and immune escape of GBM without provoking an encephalitic reaction.http://www.sciencedirect.com/science/article/pii/S1658387608500549 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Gustavo A. Moviglia Antonio G. Carrizo Gabriela Varela Carlos A. Gaeta Andrea Paes de Lima Pablo Farina Hugo Molina |
spellingShingle |
Gustavo A. Moviglia Antonio G. Carrizo Gabriela Varela Carlos A. Gaeta Andrea Paes de Lima Pablo Farina Hugo Molina Preliminary report on tumor stem cell/B cell hybridoma vaccine for recurrent glioblastoma multiforme Hematology/Oncology and Stem Cell Therapy |
author_facet |
Gustavo A. Moviglia Antonio G. Carrizo Gabriela Varela Carlos A. Gaeta Andrea Paes de Lima Pablo Farina Hugo Molina |
author_sort |
Gustavo A. Moviglia |
title |
Preliminary report on tumor stem cell/B cell hybridoma vaccine for recurrent glioblastoma multiforme |
title_short |
Preliminary report on tumor stem cell/B cell hybridoma vaccine for recurrent glioblastoma multiforme |
title_full |
Preliminary report on tumor stem cell/B cell hybridoma vaccine for recurrent glioblastoma multiforme |
title_fullStr |
Preliminary report on tumor stem cell/B cell hybridoma vaccine for recurrent glioblastoma multiforme |
title_full_unstemmed |
Preliminary report on tumor stem cell/B cell hybridoma vaccine for recurrent glioblastoma multiforme |
title_sort |
preliminary report on tumor stem cell/b cell hybridoma vaccine for recurrent glioblastoma multiforme |
publisher |
Elsevier |
series |
Hematology/Oncology and Stem Cell Therapy |
issn |
1658-3876 |
publishDate |
2008-01-01 |
description |
BACKGROUND: Glioblastoma multiforme (GBM), the most aggressive glioma, presents with a rapid evolution and relapse within the first year, which is attributed to the persistence of tumor stem cells (TSC) and the escape of immune surveillance. Mixed leukocyte culture (MLC) cytoimplant has been shown to function as a powerful intratumor pro-inflammatory cytokine pump. Tumor B-cell hybridoma (TBH) vaccines have been shown to function as antigen-presenting cells. We evaluated the toxicity and efficiency of each treatment alone and in combination. PATIENTS AND METHODS: In an open study, 12 consecutive patients were evenly divided into 3 groups, each group receiving 3 different treatments. Patients in Group 1 were treated, after diagnosis, with debulking surgery (DS)+radiotherapy (Rx), and after the first relapse underwent DS+MLC treatment. Patients in Group 2 were similarly treated but after the first relapse underwent DS+MLC+TBH. Finally, patients in Group 3 were similarly treated but after the first relapse underwent DS+TBH. Nestin PAP stain assessed TSC participation in TBH. RESULTS: Treatment with MLC had strong and rapid therapeutic effects, but was limited in duration and induced various degrees of brain inflammation. Treatment with MLC+TBH acted synergistically, provoking a rapid, strong and lasting therapeutic response but also generating different degrees of brain inflammation. A lasting therapeutic effect without generating high degrees of brain inflammation occurred in patients treated with TBH vaccine alone. CONCLUSION: TSC vaccine consisting of TBH alone seems to have potent adjuvant reactions overcoming both persistence of tumor stem cells and immune escape of GBM without provoking an encephalitic reaction. |
url |
http://www.sciencedirect.com/science/article/pii/S1658387608500549 |
work_keys_str_mv |
AT gustavoamoviglia preliminaryreportontumorstemcellbcellhybridomavaccineforrecurrentglioblastomamultiforme AT antoniogcarrizo preliminaryreportontumorstemcellbcellhybridomavaccineforrecurrentglioblastomamultiforme AT gabrielavarela preliminaryreportontumorstemcellbcellhybridomavaccineforrecurrentglioblastomamultiforme AT carlosagaeta preliminaryreportontumorstemcellbcellhybridomavaccineforrecurrentglioblastomamultiforme AT andreapaesdelima preliminaryreportontumorstemcellbcellhybridomavaccineforrecurrentglioblastomamultiforme AT pablofarina preliminaryreportontumorstemcellbcellhybridomavaccineforrecurrentglioblastomamultiforme AT hugomolina preliminaryreportontumorstemcellbcellhybridomavaccineforrecurrentglioblastomamultiforme |
_version_ |
1725215577413255168 |